Synchrogenix Appoints New CEO Kelley Kendle

WILMINGTON, Del., Nov. 20, 2014 /PRNewswire/ -- Synchrogenix Information Strategies Inc., a regulatory writing company headquartered in Wilmington, Delaware, is pleased to announce the appointment of Kelley Kendle as its new Chief Executive Officer (CEO).

Ms. Kendle has been an integral part of the Synchrogenix organization since 2003. Initially joining the company as the Director of Finance, she saw an opportunity for growth focused on regulatory writing services to the pharmaceutical and biopharmaceutical sector. With a keen understanding of the regulatory landscape, coupled with strong client relationships, Ms. Kendle has been instrumental in the development of services and the cultivation of staff to address the needs of the industry. Ms. Kendle serves as both an internal and external subject matter expert.

Upon the announcement of her new position, Ms. Kendle said, "I know we have the ability, the energy, and the commitment to make this next phase a huge success.  I can't wait to see all that we can achieve together".

Through her oversight, Synchrogenix has seen revenue increase by over 150% since 2010. As CEO, Ms. Kendle will continue to drive the company's strategic growth, business process, and organizational dynamics.

About Synchrogenix, a Certara Company

Synchrogenix, a Certaracompany, encompasses a group of separate entities operating together to provide regulatory writing services to the pharmaceutical, biotech, and medical device industries worldwide.  Synchrogenix Information Strategies Inc.; Synchrogenix Europe, Ltd.; and Synchrogenix Philippines, Inc. (SPI) are all wholly owned subsidiaries with an overall governance structure that creates and enforces a global standard of service, technology, and quality. 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.